Sustained drug delivery implant

a technology of brimonidine tartrate and implanted ocular cavity, which is applied in the direction of prosthesis, eye treatment, drug composition, etc., can solve the problems of ocular morbidity, retinal detachment, and certain limitations of intraocular use of brimonidine tartra

Inactive Publication Date: 2014-08-21
ALLERGAN INC
View PDF1 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Retinal detachments are a significant cause of ocular morbidity.
However, certain limitations exist with the use of brimonidine tartrate in intraocular implants.
For example, because of the size of the brimonidine tartrate molecule, the amount of drug that can be loaded into an implant may be limited.
Also, the hydrophilic nature of brimonidine tartrate may limit the ability of the drug's use in sustained release formulations.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sustained drug delivery implant
  • Sustained drug delivery implant
  • Sustained drug delivery implant

Examples

Experimental program
Comparison scheme
Effect test

examples

[0060]Example intraocular implants containing brimonidine tartrate or brimonidine free base and a biodegradable polymer matrix were created and tested for their release and degradation properties. The brimonidine tartrate or brimonidine free base was first weighed and blended with PLA and / or PLGA polymers in a Turbula mixer for 30 minutes. The resulting powder blend was then fed to the Haake extruder by a force feeder. The extruded filaments were cut to implants with a target weight, e.g., 857 μg or 800 μg to deliver 300 μg brimonidine tartrate or 400 μg brimonidine free base per implant. Implants were loaded into 25G applicators and gamma-sterilized at 25 to 40 kGy dose. The potency per implant was confirmed by a HPLC assay.

[0061]Examples and Comparative Examples of formulation compositions using brimonidine tartrate (as Comparative Examples 1-4) and brimonidine free base (Examples 1-4) as the drug are shown in Tables B and C, and their drug release profiles are shown in FIGS. 1 an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
lengthaaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application No. 61 / 765,554 filed on Feb. 15, 2013, the entire content of which is incorporated herein by reference.BACKGROUND[0002]1. Field[0003]The disclosure of the present application generally relates to drug delivery implants, and more specifically, drug delivery implants used to treat ocular conditions.[0004]2. Description of the Related Art[0005]Diabetic retinopathy is the leading cause of blindness among adults aged 20 to 74 years. It is estimated that 75,000 new cases of macular edema, 65,000 cases of proliferative retinopathy, and 12,000 to 24,000 new cases of blindness arise each year. Retinitis pigmentosa (RP) is a heterogeneous group of inherited neurodegenerative retinal diseases that cause the death of photoreceptor cells (rods and cones) that eventually leads to blindness. Glaucoma is a multifactorial optic neuropathy resulting from loss of retinal ganglion cells, cor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/00A61F9/00A61K31/498
CPCA61K9/0051A61K31/498A61F9/0017A61F2210/0004A61P27/02A61K47/32
Inventor SHIAH, JANE-GUOPUJARA, CHETAN
Owner ALLERGAN INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap